{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:49:57Z","timestamp":1790704197891,"version":"4.1.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>BCMA- or GPRC5D-directed CD3 bispecific antibodies are important T-cell\u2013redirecting therapies for relapsed\/refractory multiple myeloma (RRMM). We evaluated their efficacy, safety, and certainty of evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched the Cochrane Library, Embase, PubMed, Scopus, and Web of Science from inception to February 5, 2026. Prospective clinical trials and real-world studies of BCMA\u00d7CD3 or GPRC5D\u00d7CD3 bispecific antibodies in RRMM with extractable efficacy and safety data were included. Main efficacy outcomes were progression-free survival (PFS), stringent complete response (sCR), complete response (CR), complete response or better (\u2265CR), very good partial response or better (\u2265VGPR), and overall response rate (ORR). Safety outcomes included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infection, neutropenia, anemia, and thrombocytopenia. Single-arm proportional meta-analyses, sensitivity analyses, meta-regression, and subgroup analyses were performed using STATA\/MP 18.0. Methodological quality and evidence certainty were assessed using MINORS and GRADE, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen studies, including 17 independently extractable cohorts and 1,900 patients, were analyzed. The pooled PFS was 8.76 months (95% CI, 6.82\u201311.13). The pooled rates of sCR, CR, \u2265CR, \u2265VGPR, and ORR were 28.7%, 18.1%, 38.2%, 51.0%, and 65.9%, respectively. The pooled incidences of CRS, ICANS, infection, grade \u22653 infection, neutropenia, and grade \u22653 neutropenia were 67.5%, 9.7%, 60.3%, 38.3%, 54.7%, and 42.6%, respectively. MINORS showed moderate-to-high methodological quality. GRADE showed low-to-very low certainty of evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BCMA- or GPRC5D-directed CD3 bispecific antibodies showed clinically meaningful antitumor activity in RRMM. However, current evidence is mainly from single-arm trials and retrospective real-world studies, and certainty of evidence remains low to very low. These findings should be interpreted cautiously, with particular attention to infection and neutropenia in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1811816","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:48:34Z","timestamp":1779256114000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed\/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiashun","family":"Li","sequence":"first","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainikaer","family":"Abulaiti","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paerhati","family":"Wahafu","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maerdan","family":"Maimaitiming","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department Laboratory, The Six Affiliated Hospital, Xinjiang Medical University","place":["Urumqi, Xinjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"An","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangquan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maihemuti","family":"Yakufu","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1146\/annurev-med-050522-033815","article-title":"New biological therapies for multiple myeloma","volume":"75","author":"Garfall","year":"2024","journal-title":"Annu Rev Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S327016","article-title":"CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphat Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000508","article-title":"Bispecific antibody therapies","volume":"2023","author":"de Assis","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014611","article-title":"T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution","volume":"139","author":"Moreau","year":"2022","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"Anz J Surg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41408-025-01386-7","article-title":"Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"15","author":"Al Hadidi","year":"2025","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287334","article-title":"Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in Chinese patients with relapsed\/refractory multiple myeloma: efficacy and safety from the phase 1\/2 MonumenTAL-1 study","volume":"111","author":"An","year":"2026","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02841-x","article-title":"Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study","volume":"40","author":"Bar","year":"2026","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70114","article-title":"A German multicenter real-world analysis of talquetamab in 138 patients with relapsed\/refractory multiple myeloma","volume":"9","author":"Frenking","year":"2025","journal-title":"Hemasphere"},{"key":"B30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0354","article-title":"Real-world experience with teclistamab for relapsed\/refractory multiple myeloma from the US Myeloma Immunotherapy Consortium","volume":"6","author":"Razzo","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-04134-6","article-title":"Talquetamab in Japanese patients with relapsed\/refractory multiple myeloma in the MonumenTAL-1 study","volume":"123","author":"Ito","year":"2026","journal-title":"Int J Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2025.399","article-title":"Real-world efficacy and safety of teclistamab for patients with relapsed or refractory multiple myeloma: nationwide retrospective analysis of the named patient program in Korea","author":"Yi","year":"2025","journal-title":"Cancer Res Treat"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002736","article-title":"A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells","volume":"5","author":"DiLillo","year":"2021","journal-title":"Blood Adv"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1911100","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1811816\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:55:37Z","timestamp":1782122137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1811816\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1811816"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1811816","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1811816"}}